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ABSTRACT: The aim of this study was to evaluate the influence of the administration and withdrawal of cyclosporin
A/nifedipine on the bone density in a lateral area adjacent to implants placed in rabbits. Two screw-type titanium im-
plants were placed bilaterally in twenty-eight New Zealand rabbits. The animals were assigned to one of the following
groups and received daily subcutaneous injections for 14 days: Groups A and C: vehicle (dimethyl sulfoxide); Groups B
and D: CsA (10 mg/kg) plus nifedipine (50 mg/kg). The animals in Groups A and B were sacrificed 14 days postopera-
tively and, in Groups C and D, 42 days postoperatively. After sacrifice, the tibiae were removed and undecalcified sec-
tions were obtained. Bone density was obtained in a 500 m-wide zone lateral to the implant surface. Intergroup anal-
ysis showed no significant difference (p > 0.05) in the degree of bone density between control and test groups either on
day 14 or on day 42. Thus, it appears that a short-term immunosuppressive therapy may not present a negative influ-
ence on the density of the pre-existing bone around titanium implants placed in rabbits.
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RESUMO: O objetivo deste trabalho foi avaliar a influência da administração de ciclosporina A (CsA)/nifedipina e sua
interrupção na densidade óssea em uma região lateral à superfície de implantes de titânio inseridos em coelhos. Dois
implantes de titânio comercialmente puros foram inseridos bilateralmente em vinte e oito coelhos. Os animais foram
aleatoriamente divididos em um dos seguintes grupos experimentais, recebendo injeções diárias subcutâneas por
14 dias: Grupos A e C: veículo (dimetil sulfóxido); Grupos B e D: CsA (10 mg/kg) e nifedipina (50 mg/kg). Os animais
pertencentes aos Grupos A/B e C/D foram sacrificados 14 e 42 dias após a colocação dos implantes, respectivamente.
Após o sacrifício, as tíbias foram removidas para a obtenção de secções não-descalcificadas. A densidade óssea foi ob-
tida em uma zona de 500 m lateral à superfície do implante através de análise histométrica. A análise intergrupo não
revelou diferenças para os grupos teste e controle em 14 e 42 dias (p > 0,05). Dentro dos limites deste estudo podemos
concluir que a associação CsA/nifedipina, administrada em um curto prazo, não apresenta uma influência negativa
na densidade do osso preexistente ao redor de implantes de titânio inseridos em coelhos.
DESCRITORES: Titânio; Osseointegração; Ciclosporina; Nifedipina; Implantes dentários.
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INTRODUCTION
The use of titanium endosseous dental im-
plants has been described for the treatment of
edentulous or partially edentulous patients in or-
der to restore function and esthetics3,24. However,
the success of osseointegration depends on the
state of the host bone and its healing capacity.
Thus, some local and systemic conditions may im-
pair bone healing or may interfere with the mainte-
nance of osseointegration10.
Organ transplantation has increased in the last
decade following successful development of
immunosuppressive drug regimens to reduce re-
jection reports. Cyclosporin A (CsA) is the most
commonly used immunosuppressant agent for
preventing graft rejection. It is a fungal cyclic
undecapeptide, which has also shown promise in
1
the treatment of autoimmune disorders such as
psoriasis, atopic dermatitis, rheumatoid arthritis
and uveits17. Its major effect on the immune sys-
tem is inhibition of T-cell action and proliferation,
thereby altering the T-cell-mediated immune re-
sponse. It has also been shown to affect a subset of
B cells22.
In addition to its effects on the immune system,
CsA has also been associated with deleterious ef-
fects upon bone metabolism16. Nevertheless, de-
spite its many therapeutic uses and its efficient
prevention of organ rejection25, side-effects are not
infrequent. Post-transplantation osteoporosis4,15,
bone formation and bone resorption are well-rec-
ognized side-effects5,6,14,19,27. Moreover, CsA admin-
istration has been associated with gingival over-
growth and nephrotoxicity17.
In order to control hypertension and reduce
cyclosporin-induced nephrotoxicity11, patients are
frequently given nifedipine, a calcium-channel
blocker (CCBs). The effect of CCBs appears not to
be limited only to the cardiovascular system, but
also to calcium metabolism. Similarly to CsA,
nifedipine has demonstrated some effects on bone
metabolism9,29.
Therefore, the present study was designed to
evaluate, by histological analysis, whether short-
term CsA/nifedipine administration influences
bone density, in a pre-existing bone area, around
titanium implants placed in the tibiae of rabbits. In
addition, the study also aims to investigate
whether recovery is possible following administra-
tion withdrawal.
MATERIAL AND METHODS
Animals
Twenty-eight male New Zealand rabbits (3,000
to 3,500 g), aged 9 to 12 months, were used in the
entire study. The animals were kept in individual
cages with access to food and water ad libitum.
Prior to the surgical procedures, all animals were
allowed to acclimatize to the laboratory environ-
ment for a period of 7 days. The protocol was ap-
proved by the University of Campinas Institutional
Animal Care and Use Committee.
Implant surgery
At the beginning of the experiment, general an-
esthesia was performed using intramuscular ad-
ministration of ketamine (0.5 ml/kg). The tibiae
skin was shaved and disinfected with iodine surgi-
cal soap. A 30 mm incision was made and the bone
surface of the tibiae surgically exposed by blunt
dissection. Under profuse saline solution irriga-
tion, unicortical implant beds were drilled and two
screw-shaped commercially available pure tita-
nium implants (7.0 mm in length and 3.75 mm in
diameter) were placed bilaterally until the screw
thread had been completely introduced into the
bone cortex. Finally, soft tissues were replaced and
sutured. Postoperatively, the animals received an-
tibiotic (Pentabiótico®, Wyeth-Whitehall Ltda., São
Paulo, SP, Brazil) given as a single intramuscular
injection.
Experimental design
Immediately after implant placement, the ani-
mals were randomly assigned to one of the follow-
ing four treatment groups (7 animals/group) and
received daily subcutaneous injections for
14 days: Groups A and C were injected with a vehi-
cle (dimethyl sulfoxide) and groups B and D re-
ceived CsA (Sandimmun®, Novartis Pharma AG,
Switzerland) (10 mg/kg) plus nifedipine (Sigma,
St. Louis, MO, USA) (50 mg/kg). Groups A and B
were sacrificed 14 days postoperatively and
Groups C and D were sacrificed 42 days postoper-
atively (Figure 1).
Histometric procedures
After sacrifice, the tibiae were removed and
fixed in 4% neutral formalin for 48 hours.
Undecalcified sections were prepared as previ-
ously described7, i.e. the blocks were dehydrated
by using an ascending series of ethanol (60-100%)
and embedded in glycolmethacrylate (Technovit
7200; Heraeus Kulzer GmbH, Wehrheim, Ger-
many). Subsequently, sections (20-30 m) were
obtained and stained as follows: (1) the slide-con-
taining specimen was placed in a vessel containing
Stevenel’s blue preheated to 60C, and maintained
at this temperature for 15 minutes; (2) the speci-
363
Duarte PM, Nogueira Filho GR, Sallum EA, Sallum AW, Nociti Júnior FH. Short-term immunosuppressive therapy does not affect the
density of the pre-existing bone around titanium implants placed in rabbits. Pesqui Odontol Bras 2003;17(4):362-6.
FIGURE 1 - Diagram illustrating the experimental de-
sign.
2
men was rinsed in distilled water at 60C and air
dried; (3) a small amount of alizarin red stain was
placed onto the specimen surface at room temper-
ature for 5 minutes. The specimen was then
washed thoroughly in running distilled water to re-
move excess stain and air-dried. Bone density
(BD), i.e., the proportion of mineralized matrix, in a
500 m-wide zone lateral to the implant surface,
was separately recorded for both sides of the im-
plant (Image-Pro; Media Cybernetics, Silver
Spring, MD, USA).
Statistical analysis
The hypothesis that the CsA/nifedipine associ-
ation had no influence on the bone density was
tested by an intergroup analysis (Group A versus
Group B and Group C versus Group D) using
Mann-Whitney’s test ( = 0.05). In addition, to test
the hypothesis that this immunossupressant ther-
apy does not influence body weight during the ex-
perimental period, the Student’s t test was used
( = 0.05).
RESULTS
Clinical observations
On day 14, all animals showed some weight
loss. However, the animals that received
immunosuppressive therapy demonstrated a sig-
nificantly greater weight loss (–0.41  0.20 kg) than
the control group (–0.16  0.10 kg) (p = 0.01). On
day 42, after withdrawal of the immunosup-
pressive therapy, the control group presented a
weight gain (0.27  0.18 kg) and the test group still
presented some weight loss (–0.04  0.37 kg); how-
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GRAPH 1 - Mean and standard deviation of bone density
in a 500 m-wide zone lateral to the implant surface bet-
ween test and control groups on days 14 and 42.
FIGURE 2 - Photomicrographs illustrating the histologi-
cal aspects observed in a 500 m-wide zone lateral to the
implant surface. Figures A and B illustrate test groups at
14 and 42 days, respectively. (Stevenel’s blue and aliza-
rin red stain; 15.75 X).
ever, there was no statistical difference between
the groups (p = 0.07). Due to the sample variabil-
ity, these data should be considered with caution.
Histometric results
Intergroup analysis did not show statistical dif-
ference (p > 0.05) between test and control groups
regarding bone density either on day 14, during
the CsA/nifedipine administration, or on day 42,
after the withdrawal of immunosuppressive ther-
apy. Graph 1 illustrates the results observed for all
the experimental groups. Figure 2 illustrates the
histological aspects observed in the test group on
days 14 and 42.
DISCUSSION
High success rates have been reported for im-
plant-supported prostheses in fully and partially
edentulous patients3,24. However, among other fac-
tors, the medical status of the patients has been
associated with biological failures of dental
implants10. Immunosuppression is a therapeutic
regimen for several diseases17, including lifelong
medication with drug associations such as
CsA/nifedipine in order to counteract rejection of
transplanted tissues. Recently, the significance of
CsA on alveolar bone has received some atten-
tion14. Thus, with the growth in implant demand,
use of immunosuppressive therapy before or dur-
ing implantation should be considered.
Since the prognosis of an implant-supported
prosthesis may be influenced by the bone density
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around the implant, the present study aimed to
evaluate the influence of an immunosuppressive
therapy and its withdrawal on the proportion of
mineralized bone (bone density) on a 500 m-wide
zone lateral to the implant inserted in rabbits. The
results of the present study demonstrated that
short-term administration of CsA/nifedipine may
not affect the pre-existing bone adjacent to the im-
plant surface.
Increased bone remodeling and trabecular bone
loss have been observed in CsA-exposed ani-
mals8,13,21. Increased osteoblastic and decreased
osteoclastic activity in patients undergoing CsA
treatment have also been reported23. The precise
mechanisms underlying the CsA effect on bone
metabolism are still unknown. However, it may be
suggested that CsA affects the immune system by
selectively influencing the lymphokine-monokine
cascade and it has been recognized that cytokines,
such as interleukin-1, are among a number of
products of the lymphokine-monokine cascade
that affect bone metabolism20. Although in vitro
studies indicate that CsA inhibits bone resorp-
tion27, it has been observed that, in vivo, CsA ad-
ministration results in a severe high turnover
osteopenic state2,4, which is dependent on both the
dose and duration of the therapy26.
The subcutaneous route, used in this study,
has been suggested as the route of choice to pro-
vide a more consistent cycle of CsA availability
than any other route. Blood levels of CsA between
100 and 400 ng/ml have been shown to be suffi-
cient to promote immunosuppression in hu-
mans30. Likewise, in animals, blood levels between
100 and 400 ng/ml have been considered to be
effective1. The dosage of CsA used in the present
study (10 mg/kg, S.Q.) has been shown to produce
blood levels sufficient to induce immunosup-
pression in rodents12.
The most sensitive index of systemic CsA
side-effects appears to be a decrease in renal func-
tion. Calcium-channel blockers (CCB), such as
nifedipine, have been successfully utilized for the
control of CsA-induced toxicity as well as hyper-
tension11. A number of clinical and experimental
studies have suggested that the effects of CCBs are
not only limited to the cardiovascular system but
might also involve skeletal calcium metabolism,
due to the presence of calcium channels in bone
cells9,28,29. Though the mechanisms of the effects of
CCBs on bone remain obscure, some explanations
may be proposed. Calcium antagonists inhibit cal-
cium intracellular influx and there is no doubt that
calcium plays an essential role in the mechanism
for controlling bone resorption29. Osteoclast activ-
ity depends upon calcium concentration, and
CCBs can lead to a rapid increase of cytosolic free
calcium with effects on osteoclast morphology and
a marked dose-dependent fall in the cell spread
area and osteoclast bone resorption29. Clinically, it
has been reported that, in elderly patients treated
for coronary heart disease over 2 years, nifedipine
caused a temporary increase in bone mineral
density18.
CONCLUSION
In conclusion, the results of the present study
suggest that short-term administration of CsA, as-
sociated with nifedipine, may not influence bone
density in a lateral zone to the titanium implant
surface inserted in rabbits. However, further stud-
ies should be considered in order to address the
long-term consequences of maintenance dosage
schedules of CsA/nifedipine on bone mineral me-
tabolism around titanium implants.
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